Vaxart

3D rendering of SARS-CoV-2 virus particles
Biotech

Dynavax pays Vaxart $30M for oral COVID-19 vaccine program

The deal allows Dynavax to see phase 2b data before placing a bigger bet on the program.
Nick Paul Taylor Nov 6, 2025 5:50am
Make a delay and accumulation of outstanding tasks Full stop

Vaxart seeks answers as BARDA vaccine funding dries up again

Aug 12, 2025 5:08am
stop light green

HHS lifts stop work order on Vaxart's COVID-19 trial

Apr 28, 2025 12:48pm
ocean covering up money lost investment

HHS delivers stop work order to Atlanta biotech, pulls funding

Apr 16, 2025 11:02am
stop shut down close end button

Vaxart lays off staffers after HHS demands halt to vaccine trial

Mar 21, 2025 8:36am
San Francisco bridge

Biopharma largely unfazed by security concerns for JPM25

Jan 17, 2025 11:10am